SAN DIEGO, Aug. 5, 2015 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary compounded drug therapies, has expanded the availability of its proprietary ophthalmic and urologic compounded formulations to physicians and patients in Texas. The Company's expansion into the Lone Star State resulted from its recent acquisition of JT Pharmacy, Inc., d/b/a Central Allen Pharmacy, a compounding pharmacy located outside of Dallas. Imprimis' New Jersey compounding pharmacy also received licenses to dispense in Texas and Virginia.
Mark L. Baum, CEO of Imprimis, stated, "The acquisition of our third compounding pharmacy and licensure in Texas represents an important milestone for our company and for me personally because I was born and raised in Texas and have a special appreciation for its size and dynamism. Texas has experienced tremendous growth over the past several years due to its attractive tax climate, diverse economy, low unemployment, highly skilled and educated work force, affordable housing and several large and growing cities such as Dallas, Austin, San Antonio and Houston. We are confident that our investment in Texas will blossom just like a field of beautiful bluebonnets."
Mr. Baum added, "In order to take advantage of these opportunities, we have hired regional business directors in both ophthalmology and urology specifically to cover this market. We have already begun to reach out to dozens of ophthalmology practices that have expressed interest in implementing our Dropless Therapy™ in their practices. We are also looking forward to servicing the more than 800 urologists located in Texas and specifically the large patient populations that can benefit from our patented HLA compounded formulation, which is prescribed by physicians for the treatment of symptoms associated with interstitial cystitis, and our lyophilized Tri-Mix formulations for the treatment of erectile dysfunction."
To order Imprimis' compounded formulations in Texas, Virginia or in other states, physicians or their representatives should call (858) 704-4040 or visit http://imprimispharma.com/orders/ to be connected with a regional business director in their area.
ABOUT IMPRIMIS PHARMACEUTICALS
San Diego-based Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) is a pharmaceutical company dedicated to delivering high quality and innovative medicines to physicians and patients at accessible prices. Imprimis' business is focused on its proprietary ophthalmology and urology drug formulations. The company's pioneering ophthalmology formulation portfolio is disrupting the multi-billion dollar eye drop market, addressing patient compliance issues and providing other medical and economic benefits to patients. Imprimis recently launched its urology business, which includes a patented formulation to address patients suffering from interstitial cystitis and lyophilized compounded formulations for men with erectile dysfunction. For more information about Imprimis, please visit the company's corporate website at www.ImprimisPharma.com; ophthalmology business websites at www.GoDropless.com and www.LessDrops.com; and urology business websites at www.DefeatIC.com and www.EDfree.com.
All Imprimis formulations may be prescribed pursuant to a physician prescription for an individually identified patient consistent with federal and state laws governing compounded drug formulations.
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward looking statements are based on management's current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include risks and uncertainties related to Imprimis' ability to make commercially available its compounded formulations and technologies in a timely manner or at all; physician interest in prescribing its formulations; risks related to its compounding pharmacy operations; its ability to enter into other strategic alliances, including arrangements with pharmacies, physicians and healthcare organizations for the development and distribution of its formulations; its ability to obtain intellectual property protection for its assets; its ability to accurately estimate its expenses and cash burn, and raise additional funds when necessary; risks related to research and development activities; the projected size of the potential market for its technologies and formulations; unexpected new data, safety and technical issues; regulatory and market developments impacting compounding pharmacies, outsourcing facilities and the pharmaceutical industry; competition; and market conditions. These and additional risks and uncertainties are more fully described in Imprimis' filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Such documents may be read free of charge on the SEC's web site at www.sec.gov. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Except as required by law, Imprimis undertakes no obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.
Ophthalmology Sales/Marketing Contact: Etani Susman email@example.com 858.704.4494
Urology Sales/Marketing Contact: Cindi White firstname.lastname@example.org 858.704-4045
Media Contact: Deb Holliday email@example.com 412.877.4519
Investor Contact: Bonnie Ortega firstname.lastname@example.org 858.704.4587
SOURCE Imprimis Pharmaceuticals, Inc.